Latest & greatest articles for proton pump inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on proton pump inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on proton pump inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for proton pump inhibitors

181. Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies van Oijen A H, Verbeek A L, Jansen J B, de Boer W A Authors' objectives (...) To compare treatment of Helicobacter pylori infection with ranitidine bismuth citrate- and proton pump inhibitor-based triple therapies. Searching The authors searched MEDLINE and Current Contents, and manually reviewed abstracts submitted to meetings of the American Gastroenterological Association (Digestive Disease and the United European Gastroenterology weeks) and the European Helicobacter Study Group, for the period 1996 to 1999. Study selection Study designs of evaluations included in the review

DARE.2000

182. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating (...) ', 'clarithromycin', 'amoxycillin', 'omeprazole', 'lansoprazole', 'pantoprazole', 'proton pump inhibitor' and 'triple' (titles). Additional material was obtained by examining references of retrieved articles and reviews on H. pylori treatment, and by manually searching abstracts submitted to the American Gastroenterological Association congresses (1995 to 1998) and the European Helicobacter pylori Study Group congresses on H. pylori treatment (1996 to 1998). Study selection Study designs of evaluations included

DARE.2000

183. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori

Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori Gisbert J P, Gonzalez L, Calvet X, Garcia N, Lopez T, Roque M, Gabriel R, Pajares J M Authors (...) ' objectives To compare two twice-daily (b.d.), one-week triple therapies for Helicobacter pylori eradication by conducting a meta-analysis. The two therapies were a combination of a proton-pump inhibitor (PPI), clarithromycin (C) and amoxycillin (A), and a combination of PPI, C and a nitroimidazole (N). Searching The authors searched PubMed up to September 1999 (the start date was unclear). Abstracts from the International Workshop on Gastroduodenal Pathology and Helicobacter pylori, and American

DARE.2000

184. Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy

Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Helicobacter pylori eradication: proton pump inhibitor versus ranitidine bismuth citrate plus two antibiotics for 1 week. A meta-analysis of efficacy Gisbert J P, Gonzalez L, Calvet X, Roque M (...) , Gabriel R, Pajares J M Authors' objectives To compare the efficacy of proton-pump inhibitors (PPI) versus ranitidine bismuth citrate (RBC) with two antibiotics for 1 week in Helicobacter pylori (H. pylori) eradication. Searching Searches were performed in the PubMed database up to October 1999. The search strategies are reported in the paper. A manual search of abstracts from 1995 to 1999 was also undertaken from the following congresses: International Workshop on Gastroduodenal Pathology

DARE.2000

185. Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia

Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute (...) for Clinical Excellence. Guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 7. 2000 Authors' objectives To provide guidance on the use of proton pump inhibitors (PPI) in the treatment of dyspepsia. Authors' conclusions Guidance 1.1 In patients with documented duodenal or gastric ulcers, a treatment strategy of testing for Helicobacter pylori and, where positive, eradicating the infection

Health Technology Assessment (HTA) Database.2000

186. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.

Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. BACKGROUND: Heartburn affects 25% of the adult population on a monthly basis and represents the core symptom of gastro-oesophageal reflux disease (GORD). Treatment is readily available and puts a large demand on healthcare budgets. Research in the past has focused largely on the treatment of oesophagitis. A majority (...) of GORD patients show no endoscopic abnormalities and in daily practice most patients are treated empirically. OBJECTIVES: Summarise, quantify and compare the efficacy of the short-term use of proton pump inhibitors (PPI), H2-receptor antagonists (H2RA) and prokinetics in the empirical treatment of GORD and the treatment of endoscopy negative reflux disease (ENRD). SEARCH STRATEGY: Electronic searches were performed of the Cochrane Controlled Trials Register, MEDLINE and EMBASE. Bibliographies were

Cochrane2000

187. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole The importance of clarithromycin dose in the management of Helicobacter pylori infection (...) : a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole Huang J Q, Hunt R H Authors' objectives To examine the effect of seven-day triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole for Helicobacter pylori (H pylori) eradication and evaluate which dose of clarithromycin is more effective for eradicating H pylori infection. Searching Published articles and abstracts in the English language were sought

DARE.1999

188. Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H pylori eradication in peptic ulcer disease

Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H pylori eradication in peptic ulcer disease Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H pylori eradication in peptic ulcer disease Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H pylori eradication in peptic ulcer (...) disease Habu Y, Kiyota K, Inokuchi H, Sugano Y, Ko K, Waki S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Proton pump inhibitor based dual and triple therapy regimens for Helicobacter pylori eradication in peptic ulcer disease

NHS Economic Evaluation Database.1999

189. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis

Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis Harris R A, Kuppermann M, Richter J E (...) Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Proton pump inhibitors and Histamine-2 receptor antagonists in the prevention of recurrences of erosive reflux esophagitis. Type of intervention Secondary prevention. Economic study

NHS Economic Evaluation Database.1997

190. Sind Protonenpumpeninhibitoren den H2-Rezeptorantagonisten im Rahmen der H.-pylori-Eradikationstherapi uberlegen: Metaanalyse vorliegender Parallelgruppenvergleiche [Are proton pump inhibitors more potent in H. pylori eradication therapy as compared to H2

Sind Protonenpumpeninhibitoren den H2-Rezeptorantagonisten im Rahmen der H.-pylori-Eradikationstherapi uberlegen: Metaanalyse vorliegender Parallelgruppenvergleiche [Are proton pump inhibitors more potent in H. pylori eradication therapy as compared to H2 Sind Protonenpumpeninhibitoren den H2-Rezeptorantagonisten im Rahmen der H.-pylori-Eradikationstherapi uberlegen: Metaanalyse vorliegender Parallelgruppenvergleiche [Are proton pump inhibitors more potent in H. pylori eradication therapy (...) as compared to H2-receptor antagonists: meta-analysis of parallel-group studies] Sind Protonenpumpeninhibitoren den H2-Rezeptorantagonisten im Rahmen der H.-pylori-Eradikationstherapi uberlegen: Metaanalyse vorliegender Parallelgruppenvergleiche [Are proton pump inhibitors more potent in H. pylori eradication therapy as compared to H2-receptor antagonists: meta-analysis of parallel-group studies] Holtmann G, Layer P, Goebell H Authors' objectives The authors aimed to assess the available parallel-group

DARE.1996